Tramadol/ APAP
DrugTablets 37.5mg /325mg
Other names: Ultracet
NCT Number: NCT00652821
To compare the relative bioavailability of Kali and Ortho-McNeil's products
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
To compare the relative bioavailability of Kali's Tramadol/APAP 37.5mg/325mg with Ortho-McNeil's Ultracet tablets 37.5mg/325mg
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tablets 37.5mg /325mg
Other names: Ultracet
Tablets, 37.5mg/325mg
Other names: Tramadol/APAP
Time frame: 24 Hours
Par Pharmaceutical, Inc.
Industry
To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fed Conditions.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01380496
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Sainte-Foy, Quebec, Canada
View Trial DetailsNCT00652873
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Sainte-Foy, Quebec, Canada
View Trial DetailsNCT00653003
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
View Trial DetailsNCT00652600
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
View Trial Details